BPC-157.
A synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice. Studied intensively in Zagreb for three decades — the most extensively researched repair peptide in the pre-clinical literature, with a remarkably consistent healing signal.
Want the full narrative? Read the BPC-157 Research Guide for the published-study discussion and mechanism deep-dive.
- Key Signals
- Tendon · Gut · Wound
- Origin
- Synthetic (human gastric juice)
- Investigator
- Sikiric et al., Zagreb
- Class
- Pentadecapeptide (15 AA)
- Status (UAE)
- Research compound (off-label)
The Gut Peptide That Fixes Everything
Sikiric's team at Zagreb University isolates BPC-157 from human gastric juice — a 15-amino-acid peptide with unusual acid stability, 1991.
Extensive rodent studies confirm tendon, ligament, gut mucosal, and wound healing — an unusually broad pre-clinical repair signal across many labs.
Off-label use expands globally; Croatia approves an oral form (Bepecin) for gastrointestinal use. No controlled human trial data published yet.
A peptide that moves cells into action
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro
Ala-Asp-Asp-Ala-Gly-Leu-Val
C₆₂H₉₈N₁₆O₂₂ · MW 1419.5 Da
Derived from a 44-amino-acid sequence in human gastric juice protein, BPC-157 is notable for its stability across a wide pH range — resisting even the acidic gastric environment. Highly active at microgram doses.
Strong signal, zero human trials.
Preclinical data is unusually consistent across many labs; human evidence remains entirely anecdotal.
- Tendon healing (rat models)
- Gut mucosal repair (IBD)
- Wound closure acceleration
- Angiogenesis promotion
- NO pathway modulation
- Joint pain relief (reports)
- Gut healing (Bepecin use)
- Tendon recovery claims
- No controlled human trials
- Brain injury neuroprotection
- Systemic organ protection
- Anti-aging mechanisms
- Muscle growth promotion
Sign in to view the full research brief.
Mechanism deep-dive and research dosing protocols — available to registered researchers. It's free and takes under a minute.
BPC-157's Jurisdiction Gap
In the UAE, research-grade peptides occupy a defined regulatory category distinct from licensed medicines. Compounds sold under this classification — including those offered by Dubai Peptides — are intended exclusively for qualified research applications, not for human administration.
BPC-157 has no approved indication anywhere in the world, no IND filing, and no active regulatory pathway toward human approval. The preclinical record is unusually consistent across dozens of labs, but the leap from rodent data to human evidence has not been attempted in any formal trial. It remains a research chemical in every jurisdiction — widely studied, with no prescription pathway in sight.
Sikiric's group at Zagreb University isolates BPC-157 from human gastric juice; early patents filed in Croatia.
Oral BPC-157 — branded Bepecin — gains regulatory status in Croatia as a gastrointestinal supplement.
An off-label compounding market for BPC-157 exists in the UAE, operating outside the research-use classification this platform follows.